share_log

HUTCHMED Announces CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer Received By Takeda

Benzinga ·  Apr 26 08:36

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —

— Positive opinion based on results from FRESCO-2 Phase III clinical trial —

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment